Diversa schließt Deal mit Celera ab - 500 Beiträge pro Seite
eröffnet am 05.12.00 21:45:38 von
neuester Beitrag 24.12.00 22:26:21 von
neuester Beitrag 24.12.00 22:26:21 von
Beiträge: 2
ID: 312.474
ID: 312.474
Aufrufe heute: 0
Gesamt: 351
Gesamt: 351
Aktive User: 0
Top-Diskussionen
Titel | letzter Beitrag | Aufrufe |
---|---|---|
02.05.24, 18:44 | 412 | |
heute 03:02 | 207 | |
24.05.13, 08:11 | 202 | |
01.05.24, 18:36 | 197 | |
heute 03:16 | 180 | |
gestern 18:18 | 146 | |
heute 01:38 | 129 | |
27.05.14, 00:27 | 127 |
Meistdiskutierte Wertpapiere
Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
---|---|---|---|---|---|---|---|
1. | 1. | 18.440,00 | +1,28 | 298 | |||
2. | 2. | 165,15 | -3,56 | 142 | |||
3. | 4. | 4,4000 | +12,82 | 103 | |||
4. | 3. | 10,660 | +0,76 | 95 | |||
5. | 6. | 0,1960 | 0,00 | 64 | |||
6. | 5. | 6,8400 | -1,16 | 64 | |||
7. | 7. | 11,578 | -7,14 | 56 | |||
8. | 8. | 6,7190 | -1,16 | 54 |
Diversa schließt einen Deal mit Celera ab. Das ist für Diversa ein Schritt aus der Anonymität der Biotechs und damit ist DVSA auf dem Weg zum alten High.
Diversa entwickelt neue Enzyme für die Chemische Industrie, Landwirtschaft und Arztneimittelherstellung.
Celera will künftig die umfangreichen Bibliotheken von Diversa über Mikroorganismen zur detailierten Analyse nutzen und sequenzieren.
http://www2.marketwatch.com/news/yhoo/story.asp?nu=1&source=…
gruß
splatt
Diversa entwickelt neue Enzyme für die Chemische Industrie, Landwirtschaft und Arztneimittelherstellung.
Celera will künftig die umfangreichen Bibliotheken von Diversa über Mikroorganismen zur detailierten Analyse nutzen und sequenzieren.
http://www2.marketwatch.com/news/yhoo/story.asp?nu=1&source=…
gruß
splatt
Hier der Wortlaut im einzelnen:
Gene research firm Celera Genomics Group (NYSE:CRA) and biotechnology company Diversa Corp. (NASDAQ NMVSA) on Tuesday announced a collaborative agreement to sequence the genomes included in Diversa`s libraries.
Financial terms of the deal were not disclosed.
The biodiversity sequencing pact should enable new product development, the companies said in a joint statement.
The alliance will combine Celera`s industrial-scale biology systems with Diversa`s proprietary discovery technologies, including Diversa`s patented normalisation technologies, which can efficiently access previously unexplored genomes, the companies said.
The agreement expands Celera`s focus to include microbial populations, which represent the largest, untapped genetic resource on earth, the firms said.
An estimated 99 percent of microbes have never been grown or characterised and offer significant opportunities for new genetic discoveries, they added.
"Diversa`s ultra high-throughput screening is one of the most effective ways currently available to discover genes from millions of species of microbes, while sequencing provides the roadmap for the detailed genetic analysis of sets of species," Jerry Steiner, Celera`s Senior Vice President and General Manager of Discovery Services, said in the statement.
"The combination of these two complementary methods should create one of the most powerful discovery platforms in the industry," Steiner added.
Shares in Rockville, Md.-based Celera, an Applera Corp. affiliate, closed at $39-3/16 on the New York Stock Exchange on Monday. The stock has a 52-week high of $275 and a 52-week low of $34-1/2.
Shares in San Diego-based Diversa, meanwhile, finished at $16-1/2, on the Nasdaq on Monday. Diversa shares have a 52-week high of $169-3/16 and a 52-week low of $15-9/16.
Rtr 15:08 12-06-00
Selector Code: reuco
Copyright 2000, Reuters News Service
Gene research firm Celera Genomics Group (NYSE:CRA) and biotechnology company Diversa Corp. (NASDAQ NMVSA) on Tuesday announced a collaborative agreement to sequence the genomes included in Diversa`s libraries.
Financial terms of the deal were not disclosed.
The biodiversity sequencing pact should enable new product development, the companies said in a joint statement.
The alliance will combine Celera`s industrial-scale biology systems with Diversa`s proprietary discovery technologies, including Diversa`s patented normalisation technologies, which can efficiently access previously unexplored genomes, the companies said.
The agreement expands Celera`s focus to include microbial populations, which represent the largest, untapped genetic resource on earth, the firms said.
An estimated 99 percent of microbes have never been grown or characterised and offer significant opportunities for new genetic discoveries, they added.
"Diversa`s ultra high-throughput screening is one of the most effective ways currently available to discover genes from millions of species of microbes, while sequencing provides the roadmap for the detailed genetic analysis of sets of species," Jerry Steiner, Celera`s Senior Vice President and General Manager of Discovery Services, said in the statement.
"The combination of these two complementary methods should create one of the most powerful discovery platforms in the industry," Steiner added.
Shares in Rockville, Md.-based Celera, an Applera Corp. affiliate, closed at $39-3/16 on the New York Stock Exchange on Monday. The stock has a 52-week high of $275 and a 52-week low of $34-1/2.
Shares in San Diego-based Diversa, meanwhile, finished at $16-1/2, on the Nasdaq on Monday. Diversa shares have a 52-week high of $169-3/16 and a 52-week low of $15-9/16.
Rtr 15:08 12-06-00
Selector Code: reuco
Copyright 2000, Reuters News Service
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
298 | ||
142 | ||
103 | ||
95 | ||
64 | ||
64 | ||
56 | ||
54 | ||
43 | ||
42 |
Wertpapier | Beiträge | |
---|---|---|
42 | ||
40 | ||
33 | ||
31 | ||
27 | ||
26 | ||
23 | ||
22 | ||
21 | ||
21 |